Skip to main content
. 2021 Jan 18;39(3):803–811. doi: 10.1007/s10637-020-01047-5

Fig. 1.

Fig. 1

Mean (standard deviation) entrectinib and M5 plasma concentration-time profiles at steady-state in patients with advanced cancers after multiple doses of entrectinib (F1 formulation)